Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00090090 · ClinicalTrials.gov registry record · Phase 2

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

A Phase 2 study, sponsored by Spectrum Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
114
Enrollment target

NCT00090090: Completed Phase 2 study, sponsored by Spectrum Pharmaceuticals.

NCT00090090 is a Phase 2 study that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 114 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00090090, a Phase 2 study, has completed, sponsored by Spectrum Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
114 participants
Enrollment target

Study Summary

To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).

Interventions

  • DRUG Elsamitrucin

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2004-04
Est. Completion 2006-10
Phase Phase 2
Spectrum Pharmaceuticals

52 total trials

What the finished NCT00090090 record still lists

NCT00090090 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower).

The record links to 0 conditions, and to 1 intervention - of which Elsamitrucin is the first listed.

NCT00090090 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00090090 about?

NCT00090090 is a clinical study titled "Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma". To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).

What is the current status of trial NCT00090090?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2004-04. Estimated completion is 2006-10.

What interventions are being tested in trial NCT00090090?

The interventions under investigation include: Elsamitrucin (DRUG).

Who is sponsoring clinical trial NCT00090090?

This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00090090's enrollment target sits among peer trials

114 627th of 2000 higher than 1,370 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04522791 · 114 participants · Phase 2

    Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)

  • NCT04875052 · 114 participants · NA

    Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury

  • NCT05100342 · 114 participants

    Prospective Validation of a Points Score System Predicting 30-day Survival

  • NCT05224089 · 114 participants · Phase 4

    Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00090090, the US trial registry maintained by the National Library of Medicine. NCT00090090 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.